Oak Family Advisors LLC Purchases 108 Shares of Agilent Technologies, Inc. (NYSE:A)

Oak Family Advisors LLC boosted its position in Agilent Technologies, Inc. (NYSE:A) by 2.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,949 shares of the medical research company’s stock after purchasing an additional 108 shares during the quarter. Oak Family Advisors LLC’s holdings in Agilent Technologies were worth $642,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Fifth Third Bancorp increased its holdings in shares of Agilent Technologies by 2.3% during the second quarter. Fifth Third Bancorp now owns 34,173 shares of the medical research company’s stock valued at $4,430,000 after acquiring an additional 756 shares in the last quarter. Dakota Wealth Management increased its holdings in shares of Agilent Technologies by 8.6% during the second quarter. Dakota Wealth Management now owns 6,380 shares of the medical research company’s stock valued at $827,000 after acquiring an additional 505 shares in the last quarter. First Citizens Bank & Trust Co. increased its holdings in shares of Agilent Technologies by 2.5% during the second quarter. First Citizens Bank & Trust Co. now owns 7,379 shares of the medical research company’s stock valued at $957,000 after acquiring an additional 180 shares in the last quarter. Riverwater Partners LLC increased its holdings in shares of Agilent Technologies by 20.7% during the second quarter. Riverwater Partners LLC now owns 4,308 shares of the medical research company’s stock valued at $558,000 after acquiring an additional 738 shares in the last quarter. Finally, Marshall Financial Group LLC acquired a new position in shares of Agilent Technologies during the second quarter valued at about $1,058,000. 87.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on A. Evercore ISI upped their target price on Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a research report on Thursday. Jefferies Financial Group reiterated a “hold” rating and issued a $135.00 target price (down previously from $152.00) on shares of Agilent Technologies in a research report on Monday, June 3rd. JPMorgan Chase & Co. dropped their target price on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a research report on Thursday, May 30th. TD Cowen upped their target price on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday. Finally, UBS Group dropped their target price on Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating on the stock in a research report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.53.

Agilent Technologies Price Performance

Shares of NYSE:A traded up $0.23 during midday trading on Thursday, reaching $140.22. 2,622,296 shares of the company’s stock traded hands, compared to its average volume of 1,758,260. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35. The company has a market cap of $40.91 billion, a P/E ratio of 33.15, a PEG ratio of 4.86 and a beta of 1.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15. The company has a fifty day simple moving average of $133.95 and a two-hundred day simple moving average of $138.49.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same period in the prior year, the company earned $1.43 EPS. The firm’s revenue was down 5.6% compared to the same quarter last year. Equities analysts predict that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Insider Activity at Agilent Technologies

In related news, SVP Dominique Grau sold 15,000 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the sale, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Dominique Grau sold 15,000 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now owns 49,486 shares of the company’s stock, valued at $6,595,494.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,916 shares of company stock valued at $2,527,860. 0.33% of the stock is owned by insiders.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.